See the DrugPatentWatch profile for Zerbaxa
What is Zerbaxa?
Zerbaxa, also known as ceftolozane/tazobactam, is an antibiotic combination drug used to treat bacterial infections in adults. It is a beta-lactam/beta-lactamase inhibitor antibiotic [1]. Ceftolozane is a fourth-generation cephalosporin antibiotic, while tazobactam is a beta-lactamase inhibitor that helps prevent bacteria from developing resistance.
How does Zerbaxa work?
Zerbaxa works by interfering with the bacterial cell wall, causing it to weaken and eventually die. It is effective against a broad spectrum of Gram-negative bacteria, including Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, and others [2]. Zerbaxa is usually given intravenously every 8 hours in combination with a patient's water intake.
Approved indications for Zerbaxa
Zerbaxa is approved for use in the treatment of the following infections:
* Hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by Pseudomonas aeruginosa
* Complicated urinary tract infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, or Pseudomonas aeruginosa
* Complicated intra-abdominal infections caused by Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens, or Pseudomonas aeruginosa
Side effects of Zerbaxa
Common side effects of Zerbaxa include nausea, diarrhea, headache, fatigue, and infusion site reactions. More serious side effects can include allergic reactions, increased liver enzymes, and severe diarrhea (Clostridioides difficile-associated diarrhea) [3].
Patent information
The patent for Zerbaxa, held by Merck & Co., Inc. and AstraZeneca AB, expires in 2026 [4]. This has implications for biosimilars to enter the market before the exclusivity period expires.
Where can I find more information?
For more information on Zerbaxa, visit the Drugs.com website and the DrugPatentWatch.com, which provides access to the patent information as mentioned above.
Sources:
[1] https://www.drugs.com/erbaxa.html
[2] https://www.clinicaltrials.gov/ct2/show/NCT02136144
[3] https://www.emea.europa.eu/en/documents/variation Assessment report/erbaxa-H-C-PSUSA-00143-202001.pdf
[4] https://www.drugpatentwatch.com/
Please note: This article is not intended as medical advice, consult a healthcare professional for information about Zerbaxa, its use and the full scope of side effects.